Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. Additionally we are shipping NMI Proteins (10) and NMI Kits (5) and many more products for this protein.
Showing 10 out of 52 products:
Human Monoclonal NMI Primary Antibody for WB - ABIN394444
Davila, Froeling, Tan, Bonnard, Boland, Snippe, Hibberd, Seielstad: New genetic associations detected in a host response study to hepatitis B vaccine. in Genes and immunity 2010
Show all 5 references for 394444
Guinea Pig Polyclonal NMI Primary Antibody for IHC, WB - ABIN2776425
Albihn, Mo, Yang, Henriksson: Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling. in International journal of cancer. Journal international du cancer 2007
Human Monoclonal NMI Primary Antibody for IHC (p), ELISA - ABIN522559
Saito, Yukawa, Matozaki, Mikami, Yamagami, Yamagishi, Kuga, Hatayama, Nakayama: Nmi interacts with Hsp105? and enhances the Hsp105?-mediated Hsp70 expression. in Experimental cell research 2014
Cow (Bovine) Polyclonal NMI Primary Antibody for WB - ABIN2776424
Li, Lee, Avraham: A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. in The Journal of biological chemistry 2002
We propose a novel genome-wide mechanism where myosin synergizes with Pol II-associated actin to link the polymerase machinery with permissive chromatin for transcription activation.
Our observations demonstrate specific changes in the expression of myosin IC (show MYO1C Antibodies) isoform A that are concurrent with the occurrence of prostate cancer in the TRAMP (show DPT Antibodies) mouse prostate cancer model that closely mimics clinical prostate cancer
Ca(2+) binding to calmodulin induces major conformational changes in both IQ motifs and the post-IQ domain and increases flexibility of the myosin-1c tail.
The v-Crk-myosin-1c interaction, which modulates membrane dynamics by regulating Rac1 activity, is crucial for cell adhesion and spreading.
These findings suggest that Nmi is a negative regulator of the virus-triggered induction of type I IFNs that targets IRF7 (show IRF7 Antibodies)
Mouse nuclear myosin I knock-out shows interchangeability and redundancy of myosin isoforms in the cell nucleus.
Myo1c (show MYO1C Antibodies) functions as a slow transporter rather than a tension-sensitive anchor.
the novel specific NLS (show ALDH1A2 Antibodies) brings to the cell nucleus not only the "nuclear" isoform of myosin I (show MYO1A Antibodies) (NM1 (show MYO1C Antibodies) protein) but also its "cytoplasmic" isoform (Myo1c (show MYO1C Antibodies) protein)
The data suggest that Myosin 1c is involved in the cytoskeleton dynamics and membrane protein anchoring or sorting in B lymphocytes
A hearing loss-associated myo1c mutation (R156W) decreases the myosin duty ratio and force sensitivity
Data suggest that N-myc (and STAT) interactor (NMI) could improve its downstream target bradykinin B2 receptor (BDKRB2) expression to induce extracellular signal-regulated kinases (ERK) 1 (show MAPK3 Antibodies)/2 activation, and thereby further evoke malignant progression of hepatocellular carcinoma (HCC (show FAM126A Antibodies)).
N-Myc (show MYCN Antibodies)-interacting protein (NMI (show MYO1C Antibodies)) negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of NF-kappaB (show NFKB1 Antibodies)/p65 (show GORASP1 Antibodies) in histone deacetylase (show HDAC1 Antibodies)-dependent manner.
N-myc and STAT interactor sensitizes breast cancer cells to cisplatin treatment through DRAM1 (show DRAM1 Antibodies) dependent autophagy.
Results show that aberrant miR (show MLXIP Antibodies)-29 expression may account for reduced NMI (show MYO1C Antibodies) expression in breast tumors and mesenchymal phenotype of cancer cells that promotes invasive growth.
The results showed that SARS (show SARS Antibodies) coronavirus protein 6 can promote the ubiquitin-dependent proteosomal degradation of Nmi (show MYO1C Antibodies).
overexpression or depletion of NMI (show MYO1C Antibodies) revealed its regulation on G1/S progression and cell proliferation (both in vitro and in vivo), and this effect was partially dependent on STAT1 (show STAT1 Antibodies), which interacted with and was regulated by NMI (show MYO1C Antibodies).
Trim21 (show TRIM21 Antibodies) regulates Nmi (show MYO1C Antibodies)-IFI35 (show IFI35 Antibodies) complex-mediated inhibition of innate antiviral response
Its potential function in transcriptional activation of NMI (show MYO1C Antibodies).
identified NMI (show MYO1C Antibodies) induction as a novel negative feedback mechanism that decreases IRE1alpha (show ERN1 Antibodies)-dependent activation of JNK (show MAPK8 Antibodies) and apoptosis in cytokine-exposed beta cells
Thus our work reveals a novel NMI (show MYO1C Antibodies)-mediated, transcription-independent ARF (show CDKN2A Antibodies) induction pathway in response to cellular stresses.
NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. The NMI protein also interacts with all STATs except STAT2 and augments STAT-mediated transcription in response to cytokines IL2 and IFN-gamma. The NMI mRNA has low expression levels in all human fetal and adult tissues tested except brain and has high expression in cancer cell line-myeloid leukemias.
N-myc (and STAT) interactor
, N-myc and STAT interactor
, myosin I beta
, nuclear myosin I beta
, unconventional myosin-Ic
, N-myc interactor
, N-mcy (and STAT) interactor